Infiltration by lung tumor of adjacent anatomic structures including major vessels, main bronchi, and chest wall not only influences the oncologic severity of the disease but also increases the technical…
Over the last 30 years neoadjuvant treatment of stage IIIA non–small cell lung cancer (NSCLC) followed by surgical resection for stage IIIB disease has significantly improved the overall results of…
There have been recent advances in the treatment of non–small cell lung cancer (NSCLC). Surgical resection remains the cornerstone in the treatment of patients with stages I and II NSCLC….
Lung cancer and bronchogenic carcinoma are malignancies originating from the airways and pulmonary parenchyma. Most (approximately 90%) lung cancers are classified as non–small cell lung cancer. This distinction carries important…
The treatment of non–small cell lung cancer is stage specific. Aggressive staging is associated with improved stage-specific prognosis. Available methods of surgical staging include scalene node biopsy, mediastinoscopy, anterior mediastinotomy,…
Lung cancer is the most frequent cause of mortality worldwide. According to recent estimates, 222,520 new cases of lung cancer (non–small cell and small cell combined) were diagnosed and 157,300…
The seventh edition of TNM for Lung Cancer came into effect on the first of January 2011. Containing more than 100,000 cases of lung cancer treated by all modalities of…
Lung cancer classification is of paramount importance in determining the treatment for oncologic patients. Most lung cancers are non–small cell lung carcinomas (NSCLC), which are further subclassified into squamous cell…
The link between smoking and development of lung cancer has been demonstrated, not only for smokers but also for those exposed to secondhand smoke. Despite the obvious carcinogenic effects of…
Lung cancer is a global health burden and is among the most common and deadly of all malignancies worldwide. Early detection of resectable and potentially curable disease may reduce the…
